The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases
Open accessAbstract
Background & Aims The coronavirus disease 2019 (COVID-19) pandemic has affected populations, societies, and lives for more than 2 years. Long-term sequelae of COVID-19, collectively termed the postacute COVID-19 syndrome, are rapidly emerging across the globe. Here, we investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen persistence underlies the postacute COVID-19 syndrome. Methods We performed an endoscopy study with 46 patients with inflammatory bowel disease (IBD) 219 days (range, 94–257) after a confirmed COVID-19 infection. SARS-CoV-2 antigen persistence was assessed in the small and large intestine using quantitative polymerase chain reaction of 4 viral transcripts, immunofluorescence of viral nucleocapsid, and virus cultivation from biopsy tissue. Postacute COVID-19 was assessed using a standardized questionnaire, and a systemic SARS-CoV-2 immune response was evaluated using flow cytometry and enzyme-linked immunosorbent assay at endoscopy. IBD activity was evaluated using clinical, biochemical, and endoscopic means. Results We report expression of SARS-CoV-2 RNA in the gut mucosa ∼7 months after mild acute COVID-19 in 32 of 46 patients with IBD. Viral nucleocapsid protein persisted in 24 of 46 patients in gut epithelium and CD8+ T cells. Expression of SARS-CoV-2 antigens was not detectable in stool and viral antigen persistence was unrelated to severity of acute COVID-19, immunosuppressive therapy, and gut inflammation. We were unable to culture SARS-CoV-2 from gut tissue of patients with viral antigen persistence. Postacute sequelae of COVID-19 were reported from the majority of patients with viral antigen persistence, but not from patients without viral antigen persistence. Conclusion Our results indicate that SARS-CoV-2 antigen persistence in infected tissues serves as a basis for postacute COVID-19. The concept that viral antigen persistence instigates immune perturbation and postacute COVID-19 requires validation in controlled clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862 · cited 3×
“It appears plausible that viral immune perturbation and/or inflammatory tissue injury during the acute infection account for the postacute COVID-19 syndrome.(9) For example, neural accumulation of memory T cells in COVID-19 was observed in postacute COVID-19 neuropsychiatric sequelae (eg, malaise and depression) and r…”
Persistent Symptoms in Patients After Acute COVID-19
Carfì, A., Bernabei, R., Landi, F., & for the Gemelli Against COVID-19 Post-Acute Care Study Group (2020) · JAMA · doi:10.1001/jama.2020.12603 · Cited by 4,561 · cited 1×
“Considerable disagreement about definition and, thus, prevalence of postacute COVID-19 exists, ranging from 10%–87% of patients with COVID-19.(7,8) The syndrome was initially dismissed by many but is now recognized as a multi-organ disease, which reflects a significantly growing health-care challenge.”
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185 · cited 2×
“This observation strongly argues for a role of viral antigen persistence in postacute COVID-19 and it appears plausible that SARS-CoV-2 antigen persistence, possibly in infected tissues beyond the gut, could impact host immune responses underlying the postacute COVID-19 syndrome.(1) This notion is supported by an infl…”
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,176
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Management of post-acute covid-19 in primary care
Greenhalgh, T., Knight, M., A’Court, C., Buxton, M., & Husain, L. (2020) · BMJ · doi:10.1136/bmj.m3026 · Cited by 1,689
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
A minimal common outcome measure set for COVID-19 clinical research
Marshall, J. C., Murthy, S., Diaz, J., Adhikari, N. K., Angus, D. C., Arabi, Y. M., Baillie, K., Bauer, M., Berry, S., Blackwood, B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30483-7 · Cited by 1,641
SARS-CoV-2 productively infects human gut enterocytes
Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., Ravelli, R. B. G., Paul van Schayck, J., Mykytyn, A. Z., Duimel, H. Q., et al. (2020) · Science · doi:10.1126/science.abc1669 · Cited by 1,573
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples
Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., Dong, X., Yin, H., Xiao, Q., Tang, Y., Qu, X., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30083-2 · Cited by 1,547
High-dimensional characterization of post-acute sequelae of COVID-19
Al-Aly, Z., Xie, Y., & Bowe, B. (2021) · Nature · doi:10.1038/s41586-021-03553-9 · Cited by 1,518 · cited 1×
“Postacute COVID-19 typically involves symptoms including severe fatigue, cognitive dysfunction, or pain.(11) Poor baseline health status and severe acute COVID-19 convey risk for the development of postacute COVID-19, however, also mild COVID-19 (eg, in nonhospitalized patients) may culminate in postacute sequelae.”
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Phetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A., Burrell, L. M., Kent, S. J., Dore, G. J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01113-x · Cited by 1,015
WHO International Standard for anti-SARS-CoV-2 immunoglobulin
Kristiansen, P. A., Page, M., Bernasconi, V., Mattiuzzo, G., Dull, P., Makar, K., Plotkin, S., & Knezevic, I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00527-4 · Cited by 356
Datta, S. D., Talwar, A., & Lee, J. T. (2020) · JAMA · doi:10.1001/jama.2020.22717 · Cited by 316
Faecal calprotectin indicates intestinal inflammation in COVID-19
Effenberger, M., Grabherr, F., Mayr, L., Schwaerzler, J., Nairz, M., Seifert, M., Hilbe, R., Seiwald, S., Scholl-Buergi, S., Fritsche, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321388 · Cited by 305
Self-citationXie, Y., Bowe, B., & Al-Aly, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-26513-3 · Cited by 301
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection
Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Yeow, A. E. L., Garcia-Valtanen, P., Al-Delfi, Z., Gummow, J., Ferguson, C., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02228-6 · Cited by 274
Peluso, M. J., Deitchman, A. N., Torres, L., Iyer, N. S., Munter, S. E., Nixon, C. C., Donatelli, J., Thanh, C., Takahashi, S., Hakim, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109518 · Cited by 248
Lund, L. C., Hallas, J., Nielsen, H., Koch, A., Mogensen, S. H., Brun, N. C., Christiansen, C. F., Thomsen, R. W., & Pottegård, A. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00211-5 · Cited by 247
Kim, T. S., Hufford, M. M., Sun, J., Fu, Y.-X., & Braciale, T. J. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092017 · Cited by 185
Park, M., Won, J., Choi, B. Y., & Lee, C. J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0452-7 · Cited by 176
Immune signatures underlying post-acute COVID-19 lung sequelae
Cheon, I. S., Li, C., Son, Y. M., Goplen, N. P., Wu, Y., Cassmann, T., Wang, Z., Wei, X., Tang, J., Li, Y., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abk1741 · Cited by 173
Penninger, J. M., Grant, M. B., & Sung, J. J. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.07.067 · Cited by 170
S1-Leitlinie Post-COVID/Long-COVID
Koczulla, A. R., Ankermann, T., Behrends, U., Berlit, P., Böing, S., Brinkmann, F., Franke, C., Glöckl, R., Gogoll, C., Hummel, T., et al. (2021) · Pneumologie · doi:10.1055/a-1551-9734 · Cited by 158
Roukens, A. H. E., Pothast, C. R., König, M. H., Huisman, W., Dalebout, T. J., Tak, T., Azimi, S., Kruize, Y. C. M., Hagedoorn, R. S., Zlei, M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01095-w · Cited by 134
Comparison of Four SARS-CoV-2 Neutralization Assays
Riepler, L., Rössler, A., Falch, A., Volland, A., Borena, W., von Laer, D., & Kimpel, J. (2020) · Vaccines · doi:10.3390/vaccines9010013 · Cited by 117
Self-citationZollner, A., Schmiderer, A., Reider, S. J., Oberhuber, G., Pfister, A., Texler, B., Watschinger, C., Koch, R., Effenberger, M., Raine, T., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa124 · Cited by 95
Self-citationZollner, A., Watschinger, C., Rössler, A., Farcet, M. R., Penner, A., Böhm, V., Zollner-Kiechl, S., Stampfel, G., Hintenberger, R., Tilg, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103539 · Cited by 80
Self-citationTherapeutic implications of ongoing alveolar viral replication in COVID-19
McGonagle, D., Kearney, M. F., O'Regan, A. W., O’Donnell, J. S., Quartuccio, L., Watad, ., & Bridgewood, C. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00322-2 · Cited by 23
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD
Lukin, D. J., Funez-dePagnier, G., Lima, S. F., Lai, D., Duenas-Bianchi, L., Ahmed, W., Jacob, V. E., Battat, R. J., Scherl, E., & Longman, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.008 · Cited by 15
Cited by
Long COVID: major findings, mechanisms and recommendations
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00846-2 · Cited by 4,153
Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., & Boyton, R. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00904-7 · Cited by 389
Serotonin reduction in post-acute sequelae of viral infection
Wong, A. C., Devason, A. S., Umana, I. C., Cox, T. O., Dohnalová, L., Litichevskiy, L., Perla, J., Lundgren, P., Etwebi, Z., Izzo, L. T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.013 · Cited by 357
Mechanisms of long COVID and the path toward therapeutics
Peluso, M. J., & Deeks, S. G. (2024) · Cell · doi:10.1016/j.cell.2024.07.054 · Cited by 341
SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
Proal, A. D., VanElzakker, M. B., Aleman, S., Bach, K., Boribong, B. P., Buggert, M., Cherry, S., Chertow, D. S., Davies, H. E., Dupont, C. L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01601-2 · Cited by 281
Metadata
- Authors
- Zollner, A., Koch, R., Jukic, A., Pfister, A., Meyer, M., Rössler, A., Kimpel, J., Adolph, T. E., & Tilg, H.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 163
- Issue
- 2
- Pages
- 495-506.e8
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W4225258134
- Cited by
- 307
- References
- 32
- FWCI
- 32.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.